6589.TW EirGenix Inc.
- Market cap
- TWD 14.0B
- P/E
- -
- P/B
- 1.79x
- ROE
- -8.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6589.TW undervalued?
Graham numberThe Graham number of EirGenix Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EirGenix Inc. fundamental analysis
No fundamental analysis for EirGenix Inc. yet.
EirGenix Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EirGenix Inc.
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, …
Full company profileEirGenix Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EirGenix Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.70B | 1.48B | 1.02B | 1.01B | 1.01B | 1.24B |
| Gross Profit | 1.09B | 756M | 237M | 219M | 194M | 406M |
| Operating Income | -57.6M | -331M | -1.03B | -866M | -843M | -888M |
| EBITDA | - | 101M | -664M | -389M | -505M | -396M |
| Net Income | -42.6M | -116M | -915M | -698M | -761M | -672M |
| EPS | -0.14 | -0.38 | -2.99 | -2.29 | -2.51 | -2.25 |
| Balance Sheet | ||||||
| Total Assets | 11.4B | 11.8B | 11.2B | 10.9B | 10.9B | 10.6B |
| Total Liabilities | 1.01B | 1.16B | 1.15B | 1.62B | 2.61B | 2.81B |
| Shareholders' Equity | 10.4B | 10.7B | 10.0B | 9.26B | 8.34B | 7.79B |
| Cash & Short-term Investments | 6.63B | 6.13B | 5.05B | 4.10B | 3.53B | 2.86B |
| Cash Flow | ||||||
| Operating Cash Flow | -29.9M | -148M | -849M | -311M | 298M | -20.4M |
| Capital Expenditure | 170M | 788M | 729M | 928M | 1.62B | 746M |
| Free Cash Flow | -200M | -936M | -1.58B | -1.24B | -1.32B | -767M |
| Ratios | ||||||
| ROE | -0.4% | -1.1% | -9.1% | -7.5% | -9.1% | -8.6% |
| ROA | -0.4% | -1.0% | -8.2% | -6.4% | -6.9% | -6.3% |
| Net Profit Margin | -2.5% | -7.8% | -89.5% | -69.2% | -75.7% | -54.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
EirGenix Inc. dividends
EirGenix Inc. has not paid dividends in the last 5 fiscal years.
Who owns EirGenix Inc.
- Insiders 34.27%
- Institutions 11.52%
- Public & others 54.21%
- Shares outstanding 298M
- Free float 189M
EirGenix Inc. company profile
- Company name
- EirGenix Inc.
- Ticker
- 6589.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 101, Kangning Street, New Taipei City, Taiwan
- Phone
- 886 2 7708 0123
- Website
- eirgenix.com
About EirGenix Inc.
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
EirGenix Inc. management
8- Dr. Lee-Cheng LiuFounder, President, CEO, CSO & Chairman
- Ms. Hsiu-Chuan YangCFO, VP & Manager of Corporate Governance
- Dr. Chih-Jung ChangSenior VP, CEO of BMBU
- Dr. Shang-Chung JuExecutive Director & Chief Engineer
- Ms. Ching-Ying ChenExecutive Director
- Xiuquan YangAccounting Supervisor
- Dr. Ching-Wen Lin B.S, M.S, Ph.D.Senior VP & Chief Business Officer
- Dr. Klaus Martin Ph.D.Senior VP & CEO of Biopharmaceuticals Business Unit